P-103

Posaconazole solution

2.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant^®

• Empirische Formel (Hill-System): C₃₇H₄₂F₂N₈O₄
• CAS-Nummer: 171228-49-2
• Molekulargewicht: 700.78
• EG-Nummer: 200-659-6
• MDL-Nummer: MFCD00941162
• UNSPSC-Code: 41116107
• NACRES: NA.24

Eigenschaften

• Qualität: certified reference material
• Form: liquid
• Leistungsmerkmale: (Snap-N-Spike^®)
• Verpackung: ampule of 1 mL
• Hersteller/Markenname: Cerilliant^®
• Konzentration: 2.0 mg/mL in methanol
• Methode(n): gas chromatography (GC): suitable; liquid chromatography (LC): suitable
• Anwendung(en): clinical testing
• Format: single component solution
• Lagertemp.: room temp
• InChI: 1S/C37H42F2N8O4/c1-3-35(26(2)48)47-36(49)46(25-42-47)31-7-5-29(6-8-31)43-14-16-44(17-15-43)30-9-11-32(12-10-30)50-20-27-19-37(51-21-27,22-45-24-40-23-41-45)33-13-4-28(38)18-34(33)39/h4-13,18,23-27,35,48H,3,14-17,19-22H2,1-2H3/t26-,27+,35-,37-/m0/s1
• InChIKey: RAGOYPUPXAKGKH-XAKZXMRKSA-N

Beschreibung

Allgemeine Beschreibung

A certified Snap-N-Spike^® Solution suitable as starting material for calibrators, controls, or linearity standards in posaconazol therapeutic drug monitoring or clinical and diagnostic testing applications in patient blood, serum, or plasma samples by LC-MS/MS or HPLC. Sold under trade names Noxafil^® and Posanol, posaconazole is a triazole antifungal drug prescribed for treatment of invasive fungal infections in severely immunocompromised patients.

Anwendung

• Pharmacokinetic modeling in pediatric patients: Posaconazole intravenous solution and oral powder suspension formulations are studied for their pharmacokinetics in pediatric patients with neutropenia, highlighting the solution′s role in optimizing dosing regimens (Winchell et al., 2024).


• Enhanced solubility and bioavailability: Posaconazole antifungal solution is utilized in the development of amorphous solid dispersions with poly(vinylpyridine-co-vinylpyridine N-oxide) excipients, which mediate rapid dissolution and sustained supersaturation, improving its therapeutic efficacy (Liu et al., 2024).


• Nanoformulation for oral delivery: A posaconazole-loaded phospholipid-based nanoformulation developed through design of experiments, machine learning, and TOPSIS optimizes oral delivery, enhancing the antifungal′s absorption and therapeutic profile (Bayat et al., 2024).


• Cost-utility analysis in fungal prophylaxis: Research on posaconazole solution′s cost-effectiveness in preventing invasive fungal infections among leukemia patients undergoing chemotherapy underscores its potential economic benefits in healthcare settings (Pungprasert et al., 2024).


• Cerebrospinal fluid concentrations: Studies assessing the concentrations of posaconazole in cerebrospinal fluid of pediatric leukemia patients validate the solution′s penetration and potential effectiveness in treating central nervous system infections (Körholz et al., 2024).

Rechtliche Hinweise

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany

Noxafil is a registered trademark of MSD

Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Sicherheitshinweise

• Piktogramme: GHS02,GHS06,GHS08
• Signalwort: Danger
• H-Sätze: H225,H301 + H311 + H331,H370
• P-Sätze: P210 - P233 - P280 - P301 + P310 - P303 + P361 + P353 - P304 + P340 + P311
• Gefahreneinstufungen: Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1
• Zielorgane: Eyes,Central nervous system
• Lagerklassenschlüssel: 3 - Flammable liquids
• WGK: WGK 2
• Flammpunkt (°F): 49.5 °F
• Flammpunkt (°C): 9.7 °C